Limits...
The Efficacy of Gabapentin in Patients with Central Post-stroke Pain.

Hesami O, Gharagozli K, Beladimoghadam N, Assarzadegan F, Mansouri B, Sistanizad M - Iran J Pharm Res (2015)

Bottom Line: Decrease of 3 points from the initial NRS considered being clinically significant.Fisher's exact test showed no statistically significant effect of clinical and demographic characteristics of patients on their therapeutic response to gabapentin.Given the safety, efficacy, well tolerability and lack of interaction with other drugs we suggest gabapentin to be more considered as a first line therapy or as add-on therapy for reducing the pain severity in patients with thalamic syndrome.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Emam Hossein Medical and Educational Center , Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT
Thalamic pain syndrome, a type of central post-stroke pain (CPSP), may develops after a hemorrhagic or ischemic stroke and results in impairment of the thalamus. There is limited experience about gabapentin in treatment of central pains like CPSP. In a prospective observational study, the intensity of pain was recorded using the Numeric Rating Scale (NRS) at the entrance to the study. Patients eligible for treating with gabapentin, received gabapentin 300 mg twice-daily. The pain intensity was measured at entrance to the study and after one month using NRS. Decrease of 3 points from the initial NRS considered being clinically significant. From a total of 180 primarily screened patients, 84 (44 men and 40 women) were recruited. There was a significant difference between pre-treatment and post-treatment NRS (5.9 ± 2.51 vs. 4.7 ± 3.01; 95% CI: 0.442-1.962, p = 0.002). Fisher's exact test showed no statistically significant effect of clinical and demographic characteristics of patients on their therapeutic response to gabapentin. Given the safety, efficacy, well tolerability and lack of interaction with other drugs we suggest gabapentin to be more considered as a first line therapy or as add-on therapy for reducing the pain severity in patients with thalamic syndrome.

No MeSH data available.


Related in: MedlinePlus

Flowchart of the study; NRS, Numeric Rating Scale
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499431&req=5

Figure 1: Flowchart of the study; NRS, Numeric Rating Scale

Mentions: Of all 180 primarily screened patients, 93 patients entered to the study of whom 9 did not complete the study during the follow up period, and 84 patients successfully completed the study (Figure 1).


The Efficacy of Gabapentin in Patients with Central Post-stroke Pain.

Hesami O, Gharagozli K, Beladimoghadam N, Assarzadegan F, Mansouri B, Sistanizad M - Iran J Pharm Res (2015)

Flowchart of the study; NRS, Numeric Rating Scale
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499431&req=5

Figure 1: Flowchart of the study; NRS, Numeric Rating Scale
Mentions: Of all 180 primarily screened patients, 93 patients entered to the study of whom 9 did not complete the study during the follow up period, and 84 patients successfully completed the study (Figure 1).

Bottom Line: Decrease of 3 points from the initial NRS considered being clinically significant.Fisher's exact test showed no statistically significant effect of clinical and demographic characteristics of patients on their therapeutic response to gabapentin.Given the safety, efficacy, well tolerability and lack of interaction with other drugs we suggest gabapentin to be more considered as a first line therapy or as add-on therapy for reducing the pain severity in patients with thalamic syndrome.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Emam Hossein Medical and Educational Center , Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT
Thalamic pain syndrome, a type of central post-stroke pain (CPSP), may develops after a hemorrhagic or ischemic stroke and results in impairment of the thalamus. There is limited experience about gabapentin in treatment of central pains like CPSP. In a prospective observational study, the intensity of pain was recorded using the Numeric Rating Scale (NRS) at the entrance to the study. Patients eligible for treating with gabapentin, received gabapentin 300 mg twice-daily. The pain intensity was measured at entrance to the study and after one month using NRS. Decrease of 3 points from the initial NRS considered being clinically significant. From a total of 180 primarily screened patients, 84 (44 men and 40 women) were recruited. There was a significant difference between pre-treatment and post-treatment NRS (5.9 ± 2.51 vs. 4.7 ± 3.01; 95% CI: 0.442-1.962, p = 0.002). Fisher's exact test showed no statistically significant effect of clinical and demographic characteristics of patients on their therapeutic response to gabapentin. Given the safety, efficacy, well tolerability and lack of interaction with other drugs we suggest gabapentin to be more considered as a first line therapy or as add-on therapy for reducing the pain severity in patients with thalamic syndrome.

No MeSH data available.


Related in: MedlinePlus